Technology | February 23, 2015

FDA Clears X-ray-based Aortic Regurgitation Measurement Tool

Workflow uses density of contrast in the aortic root and ventricle to measure regurgitation

Pie Medical Imaging, CAAS A-Valve, qRA, angiography, heart valve repair

Image courtesy of Pie Medical Imaging

February 23, 2015 — Pie Medical Imaging BV announced that it received 510(k) clearance from the U.S. Food and Drug Administration for its CAAS A-Valve product including the quantitative Regurgitation Analysis (qRA) workflow. The qRA workflow is the first 510(k)-cleared image analysis technology to determine aortic regurgitation based on X-ray angiography

The qRA workflow provides objective and reproducible quantification of aortic regurgitation by using density of contrast in the aortic root and ventricle based on X-ray aortogram images. Visual determination is inaccurate and can lead to underestimation of regurgitation. The qRA workflow is developed to quantify the regurgitation directly after percutaneous valve replacement. In addition to the qRA workflow, CAAS A-Valve assists to define the optimal C-arm projection to place the prosthetic valve.  

“The qRA workflow is the first technology to enable an objective and reproducible method for grading aortic regurgitation on contrast aortography and can be used in clinical practice or research,” said C. Schultz, M.D., Royal Perth Hospital, The University of Western Australia.

For more information: www.piemedicalimaging.com

Related Content

Fujitsu VR Heart Simulator Viewer Features in University of Tokyo Lecture

Stereoscopic view with a heart viewer. Image courtesy of Fujitsu.

News | Simulators| September 21, 2017
September 21, 2017 — Fujitsu announced that the University of Tokyo recently used...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init